Octinoxate (Octylmethoxycinnamate) has been detected in human urine, blood and breast milk and is known for moderate risk of skin allergy. Some studies suggest that Octinoxate has estrogen like effects however less than 1% skin penetration has been found in human laboratory studies. As not much study has been done on effects of Octinoxate during breast feeding its recommended to use safe alternatives.
Octyl Methoxycinnamate (OMC) is a frequently used UV-filter in sunscreens and other cosmetics. Octinoxate can be systemically absorbed after skin application, being found in the deeper layers of the stratum corneum as well as urine, plasma, and breast milk. The mean maximum plasma concentration detected after application of 2mg/cm2 sunscreen was 7ng/mL in women and 16ng/mL in men. FDA study found blood levels 13 times above cutoff for systemic exposure.
Several studies indicated that OMC acts as an endocrine disruptor due to the ability to interfere with endocrine system at different levels. In humans OMC exposure has minor, but statistically significant effects on the levels of testosterone and estradiol. Moreover, some studies suggested that OMC can interact with the hypothalamo-pituitary-thyroid (HPT) axis.
Moreover, a study of offspring of dams treated with OMC (500–1000 mg/kg/day) showed sex-dependent behavioral changes, namely decreased motor activity in females, but not in males, and improved spatial learning in males, suggesting that OMC can affect neuronal development, however the doses used in these experiments were extremely high, not relevant to possible human exposure.Note: Study and data for tropical use only
Oxybenzone has been found in mother’s milk. And has relatively high 1% to 9% skin penetration in lab studies. Oxybenzone has relatively high rates of skin allergy, it has weak estrogen like effects, and its observed as moderate anti-androgen. Oxybenzone is associated with altered birth weight in human studies. It is not recommended to use Oxybenzone during breast feeding.Note: Study and data for tropical use only.
You should immediately inform your health care provider about Lbel Effet Parfait Spots Reducing Effect Foundation Spf 18 - Obscure 8b usage and your breastfeeding interval after usage of
Please double check with your doctor if he is aware of your breastfeeding stratus, Ask your doctor if there is any safe alternative of Lbel Effet Parfait Spots Reducing Effect Foundation Spf 18 - Obscure 8b. Check with your doctor if you shall temporally stop breastfeeding. You may go for second opinion as well. Still after all of this if your doctor still recommends Lbel Effet Parfait Spots Reducing Effect Foundation Spf 18 - Obscure 8b then go for it as they have access on more detailed medical and scientific information and they understand your individual medical situation much better.
Extreme level of monitoring required as Lbel Effet Parfait Spots Reducing Effect Foundation Spf 18 - Obscure 8b could be dangerous for kid.
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week